| Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells T Shum, B Omer, H Tashiro, RL Kruse, DL Wagner, K Parikh, Z Yi, ... Cancer discovery 7 (11), 1238-1247, 2017 | 249 | 2017 |
| Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia S Göllner, T Oellerich, S Agrawal-Singh, T Schenk, HU Klein, C Rohde, ... Nature medicine 23 (1), 69-78, 2017 | 231 | 2017 |
| Treatment of acute myeloid leukemia with T cells expressing chimeric antigen receptors directed to C-type lectin-like molecule 1 H Tashiro, T Sauer, T Shum, K Parikh, M Mamonkin, B Omer, RH Rouce, ... Molecular Therapy 25 (9), 2202-2213, 2017 | 136 | 2017 |
| Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis M Stelljes, U Krug, DW Beelen, J Braess, MC Sauerland, A Heinecke, ... Journal of clinical oncology 32 (4), 288-296, 2014 | 129 | 2014 |
| CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity T Sauer, K Parikh, S Sharma, B Omer, D Sedloev, Q Chen, L Angenendt, ... Blood, The Journal of the American Society of Hematology 138 (4), 318-330, 2021 | 119 | 2021 |
| PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation JC Albring, S Inselmann, T Sauer, C Schliemann, B Altvater, ... Bone marrow transplantation 52 (2), 317-320, 2017 | 96 | 2017 |
| Prognostic impact of Bcl-2 depends on tumor histology and expression of MALAT-1 lncRNA in non–small-cell lung cancer LH Schmidt, D Goerlich, T Spieker, C Rohde, M Schuler, M Mohr, ... Journal of Thoracic Oncology 9 (9), 1294-1304, 2014 | 79 | 2014 |
| Effects of realistic e-learning cases on students’ learning motivation during COVID-19 AK Rahm, M Töllner, MO Hubert, K Klein, C Wehling, T Sauer, ... PloS one 16 (4), e0249425, 2021 | 76 | 2021 |
| Current challenges in providing good leukapheresis products for manufacturing of CAR-T cells for patients with relapsed/refractory NHL or ALL F Korell, S Laier, S Sauer, K Veelken, H Hennemann, ML Schubert, ... Cells 9 (5), 1225, 2020 | 63 | 2020 |
| Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1 M Janssen, C Schmidt, PM Bruch, MF Blank, C Rohde, A Waclawiczek, ... Blood, The Journal of the American Society of Hematology 140 (24), 2594-2610, 2022 | 48 | 2022 |
| Modular tumor endoprostheses in surgical palliation of long-bone metastases: a reduction in tumor burden and a durable reconstruction MP Henrichs, J Krebs, G Gosheger, A Streitbuerger, M Nottrott, T Sauer, ... World Journal of Surgical Oncology 12, 1-7, 2014 | 46 | 2014 |
| Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (⩾ 60 years) M Pohlen, C Groth, T Sauer, D Görlich, R Mesters, C Schliemann, G Lenz, ... Bone marrow transplantation 51 (11), 1441-1448, 2016 | 43 | 2016 |
| Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia C Rautenberg, F Stölzel, C Röllig, M Stelljes, V Gaidzik, M Lauseker, ... Blood Cancer Journal 11 (10), 164, 2021 | 40 | 2021 |
| Transcription factor CCAAT/enhancer-binding protein alpha and critical circadian clock downstream target gene PER2 are highly deregulated in diffuse large B-cell lymphoma NH Thoennissen, GB Thoennissen, S Abbassi, S Nabavi-Nouis, T Sauer, ... Leukemia & lymphoma 53 (8), 1577-1585, 2012 | 39 | 2012 |
| Clonally resolved single-cell multi-omics identifies routes of cellular differentiation in acute myeloid leukemia S Beneyto-Calabuig, AK Merbach, JA Kniffka, M Antes, C Szu-Tu, ... Cell Stem Cell 30 (5), 706-721. e8, 2023 | 34 | 2023 |
| Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT T Sauer, G Silling, C Groth, F Rosenow, U Krug, D Görlich, G Evers, ... Bone Marrow Transplantation 50 (4), 485-492, 2015 | 34 | 2015 |
| Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to azacitidine/venetoclax A Waclawiczek, AM Leppä, S Renders, K Stumpf, C Reyneri, B Betz, ... Cancer discovery 13 (6), 1408-1427, 2023 | 33 | 2023 |
| Modeling cytokine release syndrome C Rooney, T Sauer Nature medicine 24 (6), 705-706, 2018 | 32 | 2018 |
| Pre-sensitization of malignant B cells through venetoclax significantly improves the cytotoxic efficacy of CD19. CAR-T cells M Yang, L Wang, M Ni, B Neuber, S Wang, W Gong, T Sauer, L Sellner, ... Frontiers in Immunology 11, 608167, 2020 | 30 | 2020 |
| A dynamic rRNA ribomethylome drives stemness in acute myeloid leukemia F Zhou, N Aroua, Y Liu, C Rohde, J Cheng, AK Wirth, D Fijalkowska, ... Cancer discovery 13 (2), 332-347, 2023 | 26 | 2023 |
